Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Gross Margin (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Gross Margin data on record, last reported at 22.46% in Q4 2025.

  • For Q4 2025, Gross Margin fell 1900.0% year-over-year to 22.46%; the TTM value through Dec 2025 reached 29.73%, down 566.0%, while the annual FY2025 figure was 34.53%, 1058.0% up from the prior year.
  • Gross Margin reached 22.46% in Q4 2025 per INM's latest filing, down from 35.99% in the prior quarter.
  • Across five years, Gross Margin topped out at 67.95% in Q2 2023 and bottomed at 153.07% in Q3 2022.
  • Average Gross Margin over 5 years is 23.38%, with a median of 35.99% recorded in 2025.
  • The widest YoY moves for Gross Margin: up 15542bps in 2023, down -4026bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 42.08% in 2021, then plummeted by -34bps to 27.92% in 2022, then fell by -6bps to 26.14% in 2023, then soared by 59bps to 41.46% in 2024, then plummeted by -46bps to 22.46% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 22.46% in Q4 2025, 35.99% in Q3 2025, and 44.2% in Q2 2025.